Cellectis (CLLS) Q3 2026 earnings review
Cellectis drops its lead cancer drugs as revenue falls
Cellectis abandoned its two lead blood-cancer cell therapies this quarter and pivoted to early-stage gene editing for high cholesterol. Revenue at the French biotech group fell 89% from a year ago to $4 million as research activity with partner AstraZeneca slowed. One-time restructuring and factory write-downs of $36 million pushed the operating loss to $58 million, though by our math the operating loss excluding one-offs was $22 million.
| Revenue | $3.8M -89% from a year ago |
|---|---|
| Operating loss, excluding one-offs | $21.5M $57.5M reported operating loss |
| Cash and fixed-term deposits | $146.5M $169M at the end of Q2 |
| Cash runway outlook | Unchanged at least 12 months from November 12, 2026 |
⚖️ Verdict: 🔴🔴 Very Bearish
The story got worse because halting lasme-cel and eti-cel wipes out the two fourth-quarter clinical readouts that anchored the investment case. Writing down its Raleigh and Paris cell-therapy plants by $27 million pushed shareholders' equity to negative $18 million, and the new lead programs are still in preclinical testing. One positive: stopping the cancer trials cut underlying research spending by 10% from a year ago.
The question now is whether the smaller organization can stretch its $147 million in cash and deposits long enough to bring its new gene-editing drugs into human trials or until partnered programs pay milestones. If layoffs and subleases cut quarterly burn deeply, the group buys time for preclinical development; if not, it will need fresh funding after late 2027. Full-year cash burn and a clinical timeline for .HEAL-101 will tell.
🐂 Bull Case
Halting Cancer Trials Immediately Lowered Research Costs
Cellectis develops gene-edited therapies and spends most of its money on research and clinical trials. In September, the French biotech group decided to stop developing its two internal blood-cancer drugs in order to "extend the Company's cash runway, providing financial flexibility to advance Cellectis’ in vivo gene editing pipeline through key development milestones".
While one-time restructuring charges pushed reported research and development spending up 135% from a year ago to $56.6 million, the underlying spending dropped right away. Excluding $34.9 million in factory write-downs, severance and trial close-out costs, research spending fell 9.7% from a year ago to $21.7 million by our math, because the group spent $1.6 million less on outside trial bills and $0.9 million less on staff.
What to watch: quarterly research and development cash outlays in the fourth-quarter report. A further drop once employee departures finish will show how much cash the smaller organization actually saves each quarter.
Warrant Revaluation Cushioned the Financial Loss
Cellectis holds a 40 million euro loan from the European Investment Bank (EIB) that includes stock warrants, which are rights for the lender to buy shares. Under accounting rules, the biotech group revalues those warrants every quarter and books the change in its financial income or expenses.
In the third quarter, the revaluation of the EIB warrants produced a $6.4 million non-cash gain, compared with a $7.1 million loss in the same period last year. For the first nine months of 2026, those warrant gains reached $15.1 million and helped turn the nine-month net financial result into a $5.2 million gain, whereas foreign-exchange and warrant losses created a $25.6 million net financial loss a year earlier.
What to watch: cash interest income in the full-year report. Because interest earned on bank deposits fell to $1.3 million this quarter from $2.3 million a year ago as cash reserves shrank, non-cash warrant swings will not replace real cash income.
🐻 Bear Case
Cellectis Shelved Both Lead Blood Cancer Drugs
Until this quarter, the company built its story around two off-the-shelf cell therapies for blood cancer: lasme-cel for leukemia and eti-cel for lymphoma. Earlier this year, chief executive André Choulika highlighted lasme-cel's Phase 2 trial and rejected the idea that newer in vivo approaches — treatments that edit genes directly inside a patient's body — would replace cell therapies in aggressive cancers.
On September 14, the board reversed course and chose to "exit the development of lasme-cel and eti-cel, while seeking strategic partnering opportunities to maximize their value". Better initial cancer treatments have lowered patient relapse rates, and rival antibodies and in vivo cell therapies have crowded later treatment lines, slowing trial recruitment. The group is now pivoting to "become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases", led by preclinical cholesterol and triglyceride drugs .HEAL-101 and .HEAL-201.
This reversal wipes out the two late-stage clinical readouts investors were waiting for in the fourth quarter of 2026 and replaces human trial assets with laboratory-stage programs that have not yet entered clinical testing.
What to watch: any licensing deal for lasme-cel or eti-cel, or a timeline for first-in-human trials for .HEAL-101 and .HEAL-201. Without a partner to buy the shelved cancer drugs, the internal pipeline has no unpartnered clinical-stage asset.
Factory Write-Downs Pushed Equity Below Zero
To make its own cancer cell therapies, Cellectis built specialized manufacturing plants in Raleigh, North Carolina, and Paris, France. Earlier this year, management argued that making doses in-house produced better patient response rates than hiring outside factories.
Dropping lasme-cel and eti-cel left those specialized cell-therapy plants without internal clinical trials to supply. The biotech group tested its buildings and equipment for impairment by estimating what it could earn from subleasing the space as ordinary office, manufacturing and storage facilities, assigning no extra value to the specialized cell-therapy upgrades.
- Impairment charge: $26.8 million in the third quarter ($24.8 million on equipment and improvements, $2.1 million on leases)
- Property, plant and equipment: $7.1 million at September 30, down 81.6% from $38.8 million at year-end 2025
- Total shareholders' equity: negative $17.6 million, down from positive $75.9 million at year-end 2025
What to watch: sublease agreements for the Raleigh and Paris facilities in upcoming filings. Finding tenants quickly would cut the $7.3 million the group spent on lease payments over the first nine months.
AstraZeneca Collaboration Revenue Slowed to a Trickle
Under a 2023 agreement, Cellectis and drugmaker AstraZeneca are working together to develop up to 10 cell and gene therapy candidates. The French group allocated $109.1 million of upfront cash and equity proceeds to the research plans and records revenue as it incurs research costs on those projects.
Collaboration revenue fell 90.3% from a year ago to $3.4 million in the third quarter, down from $5.0 million in the second quarter and $5.6 million in the first. Deferred income and contract liabilities — unearned payments sitting on the balance sheet waiting to be recognized as work happens — barely moved during the quarter, slipping 0.6% from $90.9 million in June to $90.4 million in September.
What to watch: quarterly collaboration revenue and deferred revenue drawdown in the fourth quarter. A continued slow drawdown would mean research work on the 10 AstraZeneca targets is moving slowly, delaying potential option fees and milestone payments.
Credit Loss Provision Added a Nine-Million-Dollar Hit
Beyond its operating labs, Cellectis carries off-balance-sheet commitments, including a lease guarantee for the Minnesota headquarters of its former agricultural unit, Calyxt, where agricultural company Cibus had agreed to indemnify the group.
In the third quarter, the biotech company booked a $9.4 million allowance for expected credit losses on a financial guarantee contract inside its financial expenses. That charge wiped out the $6.4 million non-cash gain on the European Investment Bank warrants in the quarter and left the group with a $3.9 million net financial loss for the three-month period.
What to watch: cash payments required under the financial guarantee contract in future cash-flow statements. If the guaranteed party defaults on its payments, the non-cash accounting allowance will turn into a direct cash drain on Cellectis's reserves.
👓 Other Themes
Restructuring Plan Carries Nine Million in Exit Costs
To shift its staff and labs toward in vivo gene editing, Cellectis launched a restructuring plan in the United States and France, subject to French works council consultation. The group recorded $7.1 million in employee termination benefits ($6.2 million in research and $0.9 million in administration) and $2.1 million in clinical trial close-out costs, lifting current provisions on the balance sheet from $1.2 million at year-end to $8.9 million.
💲 Other KPIs
Cash reserves shrank again as research spending outpaced partner inflows. By our math, combined cash, cash equivalents of $28.2 million and fixed-term bank deposits of $118.3 million fell by about $22.5 million from $169 million in June and from $211 million at year-end 2025. Nine-month operating cash burn reached $45.9 million, widening from $29.0 million a year earlier.
Total debt and lease obligations moved down for a third consecutive quarter. By our math, non-current and current financial liabilities plus lease debts fell to $102.4 million from $105.1 million in June and $119.9 million at the end of 2025, aided by $4.1 million in loan repayments, $7.3 million in lease payments and lower warrant liabilities.
Uncollected customer bills dropped as collaboration billings slowed. Trade receivables — money partners owe the French group for research work already billed — fell to $4.1 million at the end of September from $5.2 million in March and $14.4 million at the end of 2025, generating a $9.9 million working-capital cash inflow over the nine-month period.
🔮 Guidance
Unchanged. Cellectis stated that its $28.2 million in cash and $118.3 million in fixed-term deposits will be "sufficient to fund its operations for at least twelve months following the date the unaudited Interim Condensed Consolidated Financial Statements' were approved by our Board of Directors" on November 12, 2026, matching its prior target of funding operations into the fourth quarter of 2027.
❓ Key Questions
How far past November 2027 does the restructuring extend cash?
Management said the September restructuring was designed to extend the cash runway, yet the going-concern note only affirms funding for at least 12 months from November 2026 — the same late-2027 window given in August before canceling the two cancer trials.
When will .HEAL-101 and .HEAL-201 enter human clinical trials?
Cellectis cited preclinical proof-of-concept for its two new in vivo cholesterol and triglyceride programs, but the interim report gives no timeline for regulatory filings or first-in-human dosing.
Why did AstraZeneca collaboration revenue drop to $3.4 million?
Revenue from the AstraZeneca research plans fell from $35.0 million a year ago and $5.0 million last quarter to $3.4 million, while $90.4 million remains in deferred revenue. Investors need to know whether target research has paused or finished.
What triggered the $9.4 million credit loss on the guarantee?
The company booked a $9.4 million expected credit loss allowance on a financial guarantee contract in the third quarter. Management has not disclosed whether this stems from the $19.6 million Calyxt lease guarantee or when cash outflows might begin.